drugset / Trial / NCT04470388
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
Phase 1
Completed
25 enrolled
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates · collab
RandomizedSequentialTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.
Timeline
- Start
- 2020-09-09
- Primary completion
- 2021-08-30
- Completion
- 2021-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP-514 | Unknown | — | Oral |